Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP) - Full Text View

Purpose

The purpose of this study is to determine if the use of a silver-coated endotracheal tube (ETT) can reduce the incidence and/or delay the time of onset of VAP when compared to a non silver-coated ETT in patients who have been mechanically ventilated for >= 24 hours.

Condition	Intervention	Phase
Respiratory Failure	Device: silver salts coated endotracheal tube Device: uncoated endotracheal tube	Phase III

MedlinePlus related topics:

Pneumonia

ChemIDplus related topics:

Sodium chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Outcomes Assessor), Active Control, Factorial Assignment, Safety/Efficacy Study

Official Title:	Multi-Center Clinical Trial of the Bard Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)

Further study details as provided by C. R. Bard:

Primary Outcome Measures:

The incidence of microbiologically-confirmed VAP (mVAP), as determined by quantitative culture of bronchoalveolar lavage fluid, in subjects intubated for >=24 hours. [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

time to onset of mVAP in subjects intubated for >=24 hours [ Time Frame: 30 days ] [ Designated as safety issue: No ]
incidence of clinical VAP in subjects intubed for >=24 hours [ Time Frame: 30 days ] [ Designated as safety issue: No ]
duration of intubation [ Time Frame: unlimited ] [ Designated as safety issue: Yes ]
mortality [ Time Frame: unlimited ] [ Designated as safety issue: Yes ]
antibiotic usage [ Time Frame: unlimited ] [ Designated as safety issue: No ]
length of stay [ Time Frame: unlimited ] [ Designated as safety issue: Yes ]

Enrollment:	2003
Study Start Date:	November 2002
Study Completion Date:	March 2006
Primary Completion Date:	March 2006 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental silver salts coated endotracheal tube	Device: silver salts coated endotracheal tube intubation with silver coated tube
2: Placebo Comparator uncoated endotracheal tube	Device: uncoated endotracheal tube intubation

Detailed Description:

Nosocomial pneumonia is the leading cause of death from hospital-acquired infections.Ventilator associated pneumonia (VAP) develops in a significant percentage of patients who have been ventilated for at least 48 hours, and is associated with high morbidity, mortality,and financial costs. Silver is a well-characterized antimicrobial agent, and is the active agent in multiple medical products used to reduce or control infection. Bard has developed a proprietary antimicrobial ETT, manufactured with a hydrophilic coating containing a fine dispersion of silver salts.

This study compare the incidence and time to onset of VAP in patients intubated for >=24 hours with a proprietary silver-coated ETT versus those intubated for >= 24 hours with a standard non-coated ETT.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

age > 18 years
expected to be intubated for at least 24 hours
able to sign Informed Consent

Exclusion Criteria:

symptoms of bronchiectasis
severe hemoptysis
history of cystic fibrosis
intubated > 12 hours within previous 30 days
pregnancy
participating in a competing trial

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00148642

Locations


United States, California
	University of California, San Diego
	San Diego, California, United States, 92103

United States, Illinois
	West Suburban Hospital
	Oak Park, Illinois, United States, 60302

United States, Minnesota
	Mayo Clinic & Foundation
	Rochester, Minnesota, United States, 55905

United States, Missouri
	St. John's Mercy Medical Center
	St. Louis, Missouri, United States, 63141

United States, Texas
	Audie Murphy VA Medical Center & University Hospital
	San Antonio, Texas, United States, 78229

Sponsors and Collaborators

C. R. Bard

Investigators


Principal Investigator:	Marin H Kollef, MD	Barnes Jewish Hospital, St. Louis, MO

More Information

Publications:

Baughman RP, Spencer RE, Kleykamp BO, Rashkin MC, Douthit MM. Ventilator associated pneumonia: quality of nonbronchoscopic bronchoalveolar lavage sample affects diagnostic yield. Eur Respir J. 2000 Dec;16(6):1152-7.

Branson RD, Kollef MH. Ventilator-associated pneumonia. Respir Care. 2005 Jun;50(6):712-3. No abstract available.

Publications indexed to this study:

Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, Craven DE, Roberts PR, Arroliga AC, Hubmayr RD, Restrepo MI, Auger WR, Schinner R; NASCENT Investigation Group. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA. 2008 Aug 20;300(7):805-13.

Responsible Party:	CR Bard, Inc ( Joan Dulin )
Study ID Numbers:	5003A
First Received:	September 6, 2005
Last Updated:	May 27, 2008
ClinicalTrials.gov Identifier:	NCT00148642
Health Authority:	United States: Food and Drug Administration

Keywords provided by C. R. Bard:

ventilator-associated pneumonia

nosocomial pneumonia

Study placed in the following topic categories:

Respiratory Insufficiency

Respiratory Tract Infections

Respiratory Tract Diseases

Lung Diseases

Respiration Disorders

Pneumonia, Ventilator-Associated

Cross Infection

Pneumonia

Additional relevant MeSH terms:

Infection

ClinicalTrials.gov processed this record on October 14, 2008

Sponsored by:	C. R. Bard
Information provided by:	C. R. Bard
ClinicalTrials.gov Identifier:	NCT00148642